Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.
Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Narushima M, Muramatsu H, Morinaga S, Kajikawa K, Kato Y, Watanabe M, Zennami K, Kanao K, Morikawa N, Sumitomo M.
Nakamura K, et al. Among authors: narushima m.
J Infect Chemother. 2017 Dec;23(12):809-813. doi: 10.1016/j.jiac.2017.08.005. Epub 2017 Oct 12.
J Infect Chemother. 2017.
PMID: 28923301